A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

What Was Tested

The trial (phase 1) is built around Retatrutide.

The study will last up to 6 months and may include up to 20 visits.

It had two arms (groups): LY3437943 (experimental) and Placebo (placebo comparator).

LY3437943 administered subcutaneously (SC).

Placebo administered SC.

The registry classes the interventions as drug and other.

Who Took Part

The registry lists 85 actual participants took part.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: BMI greater than 30 kg/m2.

The full record lists 2 inclusion and 13 exclusion criteria; among the exclusions: change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study; prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity; type 1 or type 2 diabetes, history of ketoacidosis, or hyperosmolar state.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Retatrutide and who got the comparison, which limits bias.

The Retatrutide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Retatrutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2024-03-20 with completion listed for 2025-08-26.

It ran at 3 sites in United States (3).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined) (time frame: Baseline up to Week 17 (inclusive)).

It also tracked 7 secondary outcomes, for example Change from Baseline in Sleep Metabolic Rate (SMR), Change from Baseline in SMR, Change from Baseline in 24-hour Energy Expenditure (EE), Change from Baseline in 24-hour EE, Change from Baseline in Total Calorie Intake at Lunch and Change from Baseline in Total Calorie Intake at Dinner.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Retatrutide in 85 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, all human trials.